A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis
Public ClinicalTrials.gov record NCT00265096. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy (improvement of signs and symptoms) of subcutaneous (under the skin) injections of golimumab for the treatment of active psoriatic arthritis (PsA). Efficacy will be measured by reduction in the signs and symptoms of active PsA, including effects on joint pain and swelling, changes on x-ray related to joint damage, psoriasis skin lesions, physical function, and quality of life.
Study identification
- NCT ID
- NCT00265096
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 407 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2005
- Primary completion
- Apr 30, 2007
- Completion
- Dec 31, 2011
- Last update posted
- Jul 18, 2013
2005 – 2012
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | — | — |
| Not listed | La Jolla | California | — | — |
| Not listed | Upland | California | — | — |
| Not listed | Aventura | Florida | — | — |
| Not listed | Coeur d'Alene | Idaho | — | — |
| Not listed | Kansas City | Kansas | — | — |
| Not listed | Wheaton | Maryland | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Mayfield | Ohio | — | — |
| Not listed | Lake Oswego | Oregon | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Duncansville | Pennsylvania | — | — |
| Not listed | West Reading | Pennsylvania | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Edmonds | Washington | — | — |
| Not listed | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
Recently updated Arthritis, Psoriatic trials
Other public records listing Arthritis, Psoriatic. Sorted by last update posted; newest first. Not a recommendation.
- NCT04882098: A Study of Guselkumab in Participants With Active Psoriatic Arthritis Active, not recruiting
- NCT06641089: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response Recruiting
- NCT07654751: A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically Not yet recruiting
- NCT06641076: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug Active, not recruiting
- NCT06878404: A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis Active, not recruiting
- NCT06663332: A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00265096, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 18, 2013 · Synced Sep 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00265096 live on ClinicalTrials.gov.